Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

(Neutral)

(Very Positive)

Rhea-AI Summary

Rigel Pharmaceuticals (Nasdaq:RIGL) granted equity awards under its Inducement Plan, approved by the board’s Compensation Committee and made under NASDAQ Listing Rule 5635(c)(4).

The company granted 13,375 restricted stock units to six new non-executive employees, vesting over four years with 25% vesting each year.

News Market Reaction – RIGL

+5.73% 1.9x vol

10 alerts

+5.73% Session close to close

+2.8% Peak in 3 hr 53 min

$716.40M Market Cap

1.9x Rel. Volume

In the Jul 7 session, RIGL gained 5.73%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.8% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.7% in the session following this news. If shares advanced sharply following this ...

Analysis

The stock moved +5.7% in the session following this news. If shares advanced sharply following this announcement, the move would have come despite only 13,375 new RSUs being issued, a small dilution. With elevated short interest, covering activity rather than the grant size could have amplified upside.

Key Figures

Restricted stock units: 13,375 units Employees receiving awards: 6 employees Vesting period: 4 years +1 more

4 metrics

Restricted stock units 13,375 units Inducement grants to new employees under Inducement Plan

Employees receiving awards 6 employees Non-executive hires granted inducement RSUs

Vesting period 4 years RSU awards vest over four-year schedule

Annual vesting rate 25% per year One-quarter of each RSU grant vests annually

Historical Context

5 past events · Latest: Jul 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 01	Leadership change	Neutral	-2.1%	Board member appointed Executive Vice President and Chief Medical Officer.
Jun 16	Licensing agreement	Positive	+2.8%	Closed global license for FDA-approved VEPPANU with $70M upfront payment.
May 27	Conference presentation	Neutral	+1.1%	CEO scheduled to present company overview at Jefferies healthcare conference.
May 21	Data presentations	Neutral	-0.6%	Planned ASCO and EHA presentations on multiple oncology and hematology products.
May 14	Conference presentation	Neutral	-0.7%	CFO to deliver company overview at RBC Capital Markets healthcare conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news flow showed only one clearly positive licensing deal drawing a modestly positive share-price reaction, while conference and leadership items saw relatively muted, mixed responses.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), inducement plan

3 terms

restricted stock units financial

"Rigel granted 13,375 restricted stock units to six non-executive employees"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with NASDAQ Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

07/07/2026 - 08:05 AM

SOUTH SAN FRANCISCO, Calif., July 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 13,375 restricted stock units to six non-executive employees vesting over four years with 25% of the grant vesting each year.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, please visit www.rigel.com.

Contact for Investors & Media
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302818799.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

What inducement grants did Rigel Pharmaceuticals (RIGL) announce on July 7, 2026?

Rigel Pharmaceuticals granted 13,375 restricted stock units to six new non-executive employees as inducement awards. According to Rigel, these RSUs were issued under its Inducement Plan and are intended as material incentives for employees entering into employment with the company.

How do the new Rigel Pharmaceuticals (RIGL) inducement RSUs vest for employees?

The newly granted Rigel Pharmaceuticals restricted stock units vest over four years, with 25% of each grant vesting annually. According to Rigel, this time-based vesting schedule is designed to support employee retention and align new hires’ interests with long-term shareholder value.

Who is eligible for the latest Rigel Pharmaceuticals (RIGL) inducement equity awards?

The latest Rigel Pharmaceuticals inducement equity awards were granted to six non-executive employees joining the company. According to Rigel, these RSU grants are provided as material inducements to individuals entering into employment, consistent with NASDAQ Listing Rule 5635(c)(4).

Under which plan were Rigel Pharmaceuticals (RIGL) July 2026 RSU grants issued?

The July 2026 RSU grants were issued under the Rigel Pharmaceuticals Inducement Plan. According to Rigel, this plan was approved by the board’s Compensation Committee and is used specifically for inducement awards permitted under NASDAQ Listing Rule 5635(c)(4).

What does NASDAQ Listing Rule 5635(c)(4) mean for Rigel Pharmaceuticals (RIGL) inducement grants?

NASDAQ Listing Rule 5635(c)(4) allows equity awards as material inducements for new employees without shareholder approval. According to Rigel, the 13,375 RSUs granted to six non-executive employees were structured in accordance with this listing rule under its Inducement Plan.

How might Rigel Pharmaceuticals (RIGL) inducement RSU grants affect shareholders?

The inducement RSU grants modestly increase potential share count as units vest into common stock. According to Rigel, 13,375 RSUs were granted, aiming to attract and retain key non-executive employees, which the company views as supportive of its long-term business objectives.